FMP
SAO
Profarma Distribuidora de Produtos Farmacêuticos S.A., together with its subsidiaries, engages in the distribution and retail sale of pharmaceutical and hospital products in Brazil. The company operates through Distribution, and Retail segments. It provides branded medicines, generic drugs, and over-the-counter (OTC) medicines; personal hygiene, beauty, and cosmetic products, such as shampoos, conditioners, treatment creams and hair dyes, diapers and children's products, soaps , deodorants, oral care products, sunscreens, male products, cosmetics, makeup and skin products, and others; and hospital products, including injectable and infusion drugs for oncology, endocrinology, rheumatology, infectology, hematology, and other specialties. The company also offers vaccines for influenza, HPV, meningitis, hepatitis, chickenpox, dengue, and other diseases; special medicines intended for the treatment of rare and complex diseases; exclusive hygiene and beauty products, vitamins, and workshops products under the Nº21, GOnutri, and Bem Básico brands; and convenience products, including food products, pressure gauges, scales, and related products. In addition, it provides complementary services, such as promotional and logistical support, implementation of promotional campaigns, product recall, development of customized projects to offer laboratories solutions, and management of clinical procedures. As of December 31, 2019, the company operated eleven distribution centers located in the states of Alagoas, Bahia, Espírito Santo, Goiás, Minas Gerais, Paraíba, Paraná, Pernambuco, Rio Grande do Sul, Rio de Janeiro, and São Paulo, as well as approximately 196 stores in the states of Rio de Janeiro, Goiás, Tocantins, Mato Grosso, and Distrito Federal under the Drogarias Tamoio, Drogasmil, Farmalife, and Rede Rosário brands. The company was founded in 1961 and is headquartered in Rio de Janeiro, Brazil.
5.95 BRL
-0.32 (-5.38%)
EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)